Given that PD-1/PD-L1 plays a specific role in regulating T cells, and that CD300c, the target of CB201, specializes in regulating monocytes and macrophages, the respective combination therapy could potentially exert a synergistic effect in the improvement of AD symptoms. This evidence concerns the gene CD300C and Alzheimer disease.